Aβ aggregation may trigger AD pathology due to the loss of physiological function [266], while promoting osteoclast bone resorption by enhancing NF-κB activity, ERK phosphorylation, and calcium oscillatory signaling pathways, thus becoming a potential target molecule for osteoclast-associated disorders such as OP [267]. Here, NFKB1 is linked to Alzheimer disease.